Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Rheumatoid Arthritis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Rheumatoid Arthritis
    TopAbstracts in Rheumatoid Arthritis 11/13/2008 - (DGNews)
    Declining Benefit of Combination Therapy for Rheumatoid Arthritis Found in Long-Term Follow-Up of Patients: Presented at ACR-ARHP - (DGDispatch)
    Genetic Markers Point to Increased Risk of Infection in Patients With Rheumatoid Arthritis: Presented at ACR-ARHP - (DGDispatch)
    Efficacy of Rituximab Is Sustained in Patients With Rheumatoid Arthritis: Presented at ACR-ARHP - (DGDispatch)
    Tocilizumab Is Effective for Rheumatoid Arthritis in Patients With Inadequate Response to Prior Anti-TNF Treatment: Presented at ACR-ARHP - (DGDispatch)

    News archive

     Recent webcasts/CME - Rheumatoid Arthritis
      B-Cell Biology and B-Cell-Targeted Therapies for Autoimmune Rheumatic Diseases: The Role of the Allied Health Professional
      Advances in B-Cell Biology in the Treatment of Autoimmune and Inflammatory Diseases
      The Management of Difficult Rheumatoid Arthritis
      Expanding the Armamentarium for the Treatment of Juvenile Rheumatoid Arthritis: Update for Managed Care Pharmacists
      Hepatic Effects of Biologic Agents: Current and Future Issues in the Treatment of Rheumatoid Arthritis

      Webcasts/CME archive

       Recent cases - Rheumatoid Arthritis
        Adalimumab Induced Mononeuritis Multiplex in a Patient with Refractory Rheumatoid Arthritis: A Case Report
        Disseminated Cutaneous Herpes Simplex Virus-1 in a Patient with Rheumatoid Arthritis Receiving Infliximab: A Case Report
        Rheumatoid Nodule of the Thyrohyoid Membrane: A Case Report
        Recurrent Pneumothorax in a Patient with Rheumatoid Arthritis on Leflunomide Treatment: Case Report and Overview of the Literature
        Spontaneous Esophageal Perforation in a Patient with Achalasia Cardia and Rheumatoid Arthritis

        Cases archive
          




        my personal edition > rheumatoid arthritis > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Etanercept TEMPO Trial Shows Significant Remission Scores for Combination Rheumatoid Arthritis Therapy: Presented at ACR

        By Bruce Sylvester

        ORLANDO, FL -- October 28, 2003 -- Radiographic evidence indicates that etanercept monotherapy slows joint damage in rheumatoid arthritis more than methotrexate monotherapy and that concurrent combination therapy with etanercept and methotrexate achieves significantly better efficacy results at 52 weeks when compared with either drug used alone, researchers reported here on October 25th at the Annual Meeting of the American College of Rheumatology (ACR).

        "A large proportion of the combination therapy subjects achieved clinical remission, and we saw, for the first time, evidence of negative RA [rheumatoid arthritis] progression scores," said Désirée van der Heijde, MD, lead investigator of the Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes (TEMPO). Dr. van der Heijde is also a professor of rheumatology, University of Maastricht, Maastricht, The Netherlands.

        Investigators enrolled 686 subjects in the double blind, parallel-group global TEMPO study, of which 642 were included in this radiographic analysis. The subjects were randomised to etanercept 25 mg/day, methotrexate up to 20 mg/day or etanercept with methotrexate.

        Primary radiographic end point was change from baseline in van der Heijde-modified total Sharp Score (TSS) at 52 weeks. Secondary radiographic endpoints were changes in total erosions, changes in total joint space narrowing, number of eroded joints, non-progression (TSS change <=0.5 and <=3.0) and progression greater than smallest detectable difference (SDD). Two observers blinded for the sequence of the films, treatment mode and patient identity scored each X-ray. The investigators used the average of observer scores for their analysis.

        At week 52, TSS had improved to a significantly greater extent in patients taking combination therapy or etanercept alone, compared with those taking methotrexate alone.

        "Patients treated with the combination had less progression than patients treated with either monotherapy alone," the researchers reported. "Therapy with the combination resulted in statistically significant lowering of TSS compared with baseline with the entire 95% confidence interval below zero. Statistically significant differences between the groups were already present after 24 weeks of follow-up. Various sensitivity analyses, including a mixed model approach were performed and confirmed the results of the primary analysis."

        Dr. van der Heijde said that 37% of subjects treated with etanercept plus methotrexate achieved clinical remission of their disease at one year, as measured by Disease Activity Score (DAS) criteria. Eighty percent of combination subjects showed no progression of joint damage, and 51% of the same subjects reported significant improvement in functionality at week 52. "The results of this study reinforce the need for aggressive treatment of RA and help us understand the value of combination therapy," she said.


        [Study title: Radiographic Outcomes Of A Double-blind Study Of Etanercept And Methotrexate, Alone And Combined, In Patients With Active Rheumatoid Arthritis (the Tempo Trial. Abstract 206]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send